Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Popular
- How Israel’s West Bank security realities are reshaping the two-state debate
  January 27, 2026
- Syntholene Energy Corp. Announces Issuance of Key U.S. Patent Covering Proprietary Fuel Synthesis Reactor
  January 27, 2026

How Israel’s West Bank security realities are reshaping the two-state debate